Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of a Randomized Clinical Trial.

Conclusions: In statin-treated patients with recent ACS, risk of PAD events is related to lipoprotein(a) level and is reduced by alirocumab, particularly among those with high lipoprotein(a). Further study is required to confirm whether risk of VTE is related to lipoprotein(a) level and its reduction with alirocumab. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01663402.
PMID: 32223446 [PubMed - as supplied by publisher]

Source: Circulation - March 28, 2020 Category: Cardiology Authors: Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim YU, Jukema JW, Pordy R, Roe MT, White HD, Bhatt DL, ODYSSEY OUTCOMES Committees and Investigators Tags: Circulation Source Type: research